Lv42
470 积分 2024-09-27 加入
PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies
1小时前
待确认
Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers
22小时前
待确认
CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer
15天前
已完结
Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study
15天前
已完结
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy
1个月前
已完结
Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition
2个月前
已完结
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2个月前
已完结
AZD5305 More Tolerable than Earlier PARP Agents
2个月前
已完结
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
2个月前
已完结
RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)
3个月前
已完结
皖公网安备34019202002308
